Reviews

6. Probing the free-state solution behavior of drugs and their tendencies to self-aggregate into nano-entities.

LaPlante SR, Roux V, Shahout F, LaPlante G, Woo S, Denk MM, Larda ST, Ayotte Y., Nat Protoc., 2021 Nov;16(11):5250-5273. doi: 10.1038/s41596-021-00612-3.

5. Peptides as Leads for Drug Discovery

Edwards, Paul J.; LaPlante, Steven R. - Edited by Castanho, Miguel; Santos, Nuno C , Peptide Drug Discovery and Development (2011), 3-55.

​

4. Assessing Atropisomer Axial Chirality in Drug Discovery and Development

LaPlante, Steven R.; Fader, Lee D.; Fandrick, Keith R.; Fandrick, Daniel R.; Hucke, Oliver; Kemper, Ray; Miller, Stephen P. F.; Edwards, Paul J.

Journal of Medicinal Chemistry (2011), 54, 20, 7005-7022.

​

3. The Challenge of Atropisomerism in Drug Discovery

Clayden, Jonathan; Moran, Wesley J.; Edwards, Paul J.; LaPlante, Steven R.

Angewandte Chemie, International Edition (2009), 48, 35, 6398-6401.

​

2. Exploiting Ligand and Receptor Adaptability in Rational Drug Design Using Dynamics and Structure-based Strategies

LaPlante, Steven R.

Topics in Current Chemistry (2007), 272 (Bioactive Conformation I), 259-296.

​

1. Dynamics and Structure-based Design of Drugs Targeting the Critical Serine Protease of the Hepatitis C Virus - From a Peptidic Substrate to BILN 2061

LaPlante, Steven R.; Llinas-Brunet, Montse

Current Medicinal Chemistry: Anti-Infective Agents (2005), 4, 2, 111-132.